Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Accumulated Expenses (2016 - 2026)

OptimizeRx's Accumulated Expenses history spans 16 years, with the latest figure at $11.6 million for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 36.59% to $11.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.6 million, a 36.59% increase, with the full-year FY2025 number at $11.6 million, up 36.59% from a year prior.
  • Accumulated Expenses hit $11.6 million in Q4 2025 for OptimizeRx, up from $10.2 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for OPRX hit a ceiling of $12.5 million in Q2 2025 and a floor of $869791.0 in Q1 2021.
  • Historically, Accumulated Expenses has averaged $5.0 million across 5 years, with a median of $3.0 million in 2021.
  • Biggest five-year swings in Accumulated Expenses: plummeted 48.06% in 2021 and later skyrocketed 253.18% in 2024.
  • Tracing OPRX's Accumulated Expenses over 5 years: stood at $2.9 million in 2021, then decreased by 10.39% to $2.6 million in 2022, then skyrocketed by 196.24% to $7.7 million in 2023, then increased by 10.12% to $8.5 million in 2024, then soared by 36.59% to $11.6 million in 2025.
  • Business Quant data shows Accumulated Expenses for OPRX at $11.6 million in Q4 2025, $10.2 million in Q3 2025, and $12.5 million in Q2 2025.